Trend Analysis Report on Biotech Stocks: IDIX, SQNM, MNKD, INO, EXEL

Scottsdale, AZ -- (SBWIRE) -- 01/25/2013 -- Universal pennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) ended higher by 0.32 points or 7.29% to complete the day at 4.71. The total number of shares changed hands during the day was 2.72 million. After opening at $4.41, the stock hit as high as $4.75. However, it traded between $3.35 and$15.17 over the last twelve months. Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and Europe.

For How Long IDIX will Fight for Profitability? Read This Trend Analysis report

Sequenom, Inc. (NASDAQ:SQNM) closed yesterday at $4.17, a 0.48% increase. Around 2.58 million shares were traded, down from an-average trading volume of 3.92 million shares. The company is now valued at around $478.66 million. Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research.

For How Long SQNM’s Gloss will Attract Investors? Find out via this report

MannKind Corporation (NASDAQ:MNKD) moved -1.15 per cent lower at $2.58 and traded between $2.55 and $2.64 after opening the day at $2.63. Its performance over the last five days remained -0.39%, which stands at 17.27% for a month. Going back further than one month, 1-year performance after recent close was -8.51%. MannKind Corporation, a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.

Will MNKD Get Buyers Even After The Recent Rally? Find Out Here

Inovio Pharmaceuticals, Inc. (NYSE:INO) shares decline, decreasing -5.80 per cent to close at $0.650. The stock is up around 30.13% this year and 52.58% for the last 12 months. Around 1.67 million shares changed hands yesterday, higher from an-average trading volume of 1.46 million shares. Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases.

Why Should Investors Buy INO After the Recent Fall? Just Go Here and Find Out

The share price of Exelixis, Inc. (NASDAQ:EXEL) after ranging between $4.57 and $4.73 ended -0.65% lower to settle at $4.59.During the past 52 weeks, the stock has ranged from a high of $6.95 to a low of $4.19.So far this year, shares have gained 0.44% and 1-year performance was around -8.2%. Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer.

Has EXEL Found The Bottom And Ready To Gain Momentum? Find Out Here

About Universal Penny Stocks
Universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.